Hit enter to search or ESC to close

Investor Overview

Sign up for our investor alerts

Receive press releases, news and updates from Alterity Therapeutics.

Creating an alternate future
for people living with
neurodegenerative diseases.

Alterity Therapeutics is a clinical stage biotechnology company focused on neurodegenerative diseases. Alterity’s lead candidate, ATH434, is the first of a new generation of small molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce α-synuclein pathology and preserve nerve cells by restoring normal iron balance in the brain. In this way, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 is currently in a Phase 2 clinical trial in MSA. Alterity also has a broad drug discovery platform generating patentable chemical compounds to intercede in disease processes.

Investment highlights

Highly experienced board and management team with proven track record and multiple U.S. FDA approvals
ATH434 is a novel drug candidate targeting key proteins implicated in neurodegeneration in various Parkinsonian disorders
Ongoing Phase 2 clinical trial with ATH434 for patients suffering from Multiple System Atrophy (MSA), a devastating disease with no approved treatments
Orphan Drug designation granted in the U.S. and EU for ATH434 for the treatment of MSA
Drug discovery team generating patentable compounds as next generation therapies

Financial Summary

Quarterly Report – 31 March 2022

Download here

Half Year Report Ending 31 December 2021

Download here

Annual Report – 30 June 2021

Download here



Data Provided by TradingView. Minimum 15 minutes delayed.

Contact Investor Relations


Rebecca Wilson

[email protected]


Remy Bemarda

[email protected]

Receive news from Alterity Therapeutics